Abstract
*Warren Alpert School of Medicine of Brown University, 222 Richmond St, Providence, RI 02903, USA; kperez@lifespan.org Total neoadjuvant treatment of rectal cancer – the concept of administering all cycles of systemic chemotherapy followed by radiation with concurrent fluoropyrimidine prior to surgical resection – has been evaluated in Phase II studies. Is there adequate data to consider this approach an acceptable standard of care? Can we use total neoadjuvant treatment as the new model to incorporate targeted agents, or must we await what would unquestionably be a dull, tedious and inexorably long Phase III trial comparing preoperative versus postoperative systemic chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
